In order to address the possibility of KRAS mutation being detected only in the circulating plasma DNA and not in the tumor tissue, our findings agree with the previous studies, where the discordant result of primary tissue (wild-type) and plasma (mutant) has been also described in colorectal cancers [22] and pancreatic cancers [23]. Here, KRAS is linked to pancreatic neoplasm.